Requires health insurance and Medicaid coverage for testing and treatments to slow progression of Alzheimer's disease and related disorders.
Summary
Assembly Bill 5062 requires a broad set of New Jersey health coverage arrangements to pay for medically necessary diagnostic testing and U.S. Food and Drug Administration-approved treatments or medications prescribed to slow the progression of Alzheimer’s disease and related disorders. The mandate applies to hospital, medical, and health service corporations; individual and group health insurance policies; individual and small employer health benefits plans; health maintenance organization contracts; the State Health Benefits Program; the School Employees’ Health Benefits Program; and Medicaid. Coverage must be provided when determined medically necessary by a physician and used in accordance with the FDA label.
The bill also bars step therapy requirements for FDA-approved treatments or medications covered under the act. It applies to policies and contracts delivered, issued, executed, or renewed on or after the effective date, which is 180 days after enactment. The Department of Human Services would be required to seek any state plan amendments or waivers needed to implement the Medicaid portion and obtain federal matching funds.
Impact
The bill would expand mandated benefits under New Jersey insurance law and require Medicaid coverage for Alzheimer’s-related diagnostic testing and disease-slowing treatments. It affects multiple statutory insurance frameworks, including hospital service corporations, medical service corporations, health service corporations, individual and group policies, health benefits plans, HMOs, and the state employee health benefit programs. By prohibiting step therapy for these treatments, it would limit utilization-management tools that insurers and managed care programs might otherwise use.
Sentiment
Based on the bill’s text and sponsor statement, the measure appears strongly supportive of patients with Alzheimer’s disease and related disorders, with an emphasis on improving access to emerging FDA-approved therapies and necessary testing. No committee transcript or recorded vote information is provided, so there is no documented opposition or amendment debate in the available materials. The overall framing suggests a patient-access and coverage-expansion approach rather than a contested policy redesign.
Contention
The main likely point of contention is cost and coverage administration, since the bill mandates benefits across private insurance, state employee plans, and Medicaid, and requires the state to pursue federal approval for Medicaid financing. Another potential issue is the prohibition on step therapy, which may concern insurers and managed care entities that use prior-treatment protocols to manage costs and clinical sequencing. The bill’s supporters would likely emphasize access for patients and physician-directed care, while any critics would likely focus on premium impacts, Medicaid spending, and reduced insurer utilization controls.